https://dev.oncoprescribe.com/erbitux-cetuximab/2020-05-06T14:57:10-07:00https://dev.oncoprescribe.com/kyprolis-carfilzomib-injection/2020-05-06T14:44:29-07:00https://dev.oncoprescribe.com/afinitor-everolimus-tablets/2020-05-06T14:58:05-07:00https://dev.oncoprescribe.com/synribo-omacetaxine-mepesuccinate/2020-05-06T14:44:00-07:00https://dev.oncoprescribe.com/rituxan-rituximab/2020-05-06T14:59:13-07:00https://dev.oncoprescribe.com/alimta-pemetrexed/2020-05-07T08:38:21-07:00https://dev.oncoprescribe.com/abraxane-paclitaxel-albumin-bound-particles/2020-05-07T08:39:36-07:00https://dev.oncoprescribe.com/stivarga-regorafenib/2020-05-07T08:40:37-07:00https://dev.oncoprescribe.com/bosulif-bosutinib/2020-05-07T08:41:19-07:00https://dev.oncoprescribe.com/xtandi-enzalutamide/2020-05-07T08:41:38-07:00https://dev.oncoprescribe.com/afinitor-everolimus/2020-05-07T08:42:04-07:00https://dev.oncoprescribe.com/marqibo-vincristine-sulfate-liposome-injection/2020-05-07T08:43:02-07:00https://dev.oncoprescribe.com/zaltrap-ziv-aflibercept-injection/2020-05-07T08:44:03-07:00https://dev.oncoprescribe.com/px-171-003-a1-an-open-label-single-arm-phase-ph-ii-study-of-carfilzomib-cfz-in-patients-pts-with-relapsed-and-refractory-multiple-myeloma-r-r-mm-long-term-follow-up-and-subgroup-analysis/2020-05-23T18:44:58-07:00https://dev.oncoprescribe.com/FDA-approves-STIVARGA-Regorafenib-for-Advanced-Colorectal-Cancer/2012-09-30T19:58:45-07:00https://dev.oncoprescribe.com/Bosutinib-as-third-line-therapy-for-chronic-phase-CP-chronic-myeloid-leukemia-CML-following-failure-with-imatinib-and-dasatinib-or-nilotinib/2012-09-23T18:58:32-07:00https://dev.oncoprescribe.com/XTANDI-Enzalutamide-now-approved-for-Late-Stage-Prostate-Cancer/2012-09-07T13:36:49-07:00https://dev.oncoprescribe.com/Preoperative-Chemoradiotherapy-for-Esophageal-or-Junctional-Cancer/2012-08-06T22:08:43-07:00https://dev.oncoprescribe.com/Prevention-of-Pegfilgrastim-Induced-Bone-Pain-A-Phase-III-Double-Blind-Placebo-Controlled-Randomized-Clinical-Trial-of-the-University-of-Rochester-Cancer-Center-Clinical-Community-Oncology-Program-Re/2012-08-06T21:23:52-07:00https://dev.oncoprescribe.com/Radical-Prostatectomy-versus-Observation-for-Localized-Prostate-Cancer/2012-07-30T23:14:47-07:00https://dev.oncoprescribe.com/Adjuvant-Therapy-in-the-Treatment-of-Biliary-Tract-Cancer-A-Systematic-Review-and-Meta-AnalysisAdjuvant-Therapy-in-the-Treatment-of-Biliary-Tract-Cancer-A-Systematic-Review-and-Meta-Analysis/2012-07-22T19:06:21-07:00https://dev.oncoprescribe.com/The-use-of-olanzapine-versus-metoclopramide-for-the-treatment-of-breakthrough-chemotherapy-induced-nausea-and-vomiting-CINV-in-patients-receiving-highly-emetogenic-chemotherapy/2012-06-14T09:25:03-07:00https://dev.oncoprescribe.com/intermittent-iad-versus-continuous-androgen-deprivation-cad-in-hormone-sensitive-metastatic-prostate-cancer-hsm1pc-patients-pts-results-of-s9346-int-0162-an-international-phase-iii-trial/2020-04-05T18:33:22-07:00https://dev.oncoprescribe.com/effect-of-neoadjuvant-abiraterone-acetate-aa-plus-leuprolide-acetate-lhrha-on-psa-pathological-complete-response-pcr-and-near-pcr-in-localized-high-risk-prostate-cancer-lhrpc-results-of-a-r/2020-04-05T18:32:32-07:00https://dev.oncoprescribe.com/bendamustine-plus-rituximab-b-r-versus-chop-plus-rituximab-chop-r-as-first-line-treatment-in-patients-with-indolent-and-mantle-cell-lymphomas-mcl-updated-results-from-the-stil-nhl1-study/2020-04-05T18:31:48-07:00https://dev.oncoprescribe.com/Phase-III,-randomized,-open-label,-multicenter-trial-BREAK-3-comparing-the-BRAF-kinase-inhibitor-dabrafenib-GSK2118436-with-dacarbazine-DTIC-in-patients-with-BRAFV600E-mutated-melanoma/2012-06-12T08:29:20-07:00https://dev.oncoprescribe.com/METRIC-phase-III-study-Efficacy-of-trametinib-T,-a-potent-and-selective-MEK-inhibitor-MEKi,-in-progression-free-survival-PFS-and-overall-survival-OS,-compared-with-chemotherapy-C-in-patient/2012-06-09T17:06:04-07:00https://dev.oncoprescribe.com/Randomized-phase-III-trial-of-orafenib-in-patients-pts-with-metastatic-and/or-unresectable-gastrointestinal-stromal-tumor-GIST-progressing-despite-prior-treatment-with-at-least-imatinib-IM-an/2012-06-05T21:35:01-07:00https://dev.oncoprescribe.com/lux-lung-3-a-randomized-open-label-phase-iii-study-of-afatinib-versus-pemetrexed-and-cisplatin-as-first-line-treatment-for-patients-with-advanced-adenocarcinoma-of-the-lung-harboring-egfr-activatin/2020-04-05T18:30:46-07:00https://dev.oncoprescribe.com/AURELIA-A-randomized-phase-III-trial-evaluating-bevacizumab-BEV-plus-chemotherapy-CT-for-platinum-PT-resistant-recurrent-ovarian-cancer-OC/2012-06-04T00:55:22-07:00https://dev.oncoprescribe.com/safety-activity-and-immune-correlates-of-anti-ndash-pd-1-antibody-in-cancer/2020-05-07T08:37:09-07:00https://dev.oncoprescribe.com/primary-results-from-emilia-a-phase-iii-study-of-trastuzumab-emtansine-t-dm1-versus-capecitabine-x-and-lapatinib-l-in-her2-positive-locally-advanced-or-metastatic-breast-cancer-mbc-previously/2020-04-05T18:28:10-07:00https://dev.oncoprescribe.com/outcomes-after-induction-failure-in-childhood-acute-lymphoblastic-leukemia/2020-05-07T08:36:33-07:00https://dev.oncoprescribe.com/Continuous-Lenalidomide-Treatment-for-Newly-Diagnosed-Multiple-Myeloma/2012-05-10T08:57:59-07:00https://dev.oncoprescribe.com/Lenalidomide-after-Stem-Cell-Transplantation-for-Multiple-Myeloma/2012-05-10T08:48:43-07:00https://dev.oncoprescribe.com/everolimus-in-postmenopausal-hormone-receptor-ndash-positive-advanced-breast-cancer/2020-05-23T17:47:34-07:00https://dev.oncoprescribe.com/effect-of-mdv3100-an-androgen-receptor-signaling-inhibitor-arsi-on-overall-survival-in-patients-with-prostate-cancer-post-docetaxel-results-from-the-phase-iii-affirm-study/2020-04-05T18:26:15-07:00https://dev.oncoprescribe.com/results-of-a-phase-iii-randomized-double-blind-placebo-controlled-multicenter-trial-correct-of-orafenib-plus-best-supportive-care-bsc-versus-placebo-plus-bsc-in-patients-pts-with-metastati/2020-04-05T18:24:58-07:00https://dev.oncoprescribe.com/risk-factors-for-breast-cancer-for-women-aged-40-to-49-years/2020-05-23T17:49:13-07:00https://dev.oncoprescribe.com/bevacizumab-bev-plus-chemotherapy-ct-continued-beyond-first-progression-in-patients-with-metastatic-colorectal-cancer-mcrc-previously-treated-with-bev-plus-ct-results-of-a-randomized-phase-iii/2020-04-05T18:23:51-07:00https://dev.oncoprescribe.com/pertuzumab-plus-trastuzumab-plus-docetaxel-for-metastatic-breast-cancer/2020-05-23T17:48:34-07:00https://dev.oncoprescribe.com/Radiotherapy-with-or-without-Chemotherapy-in-Muscle-Invasive-Bladder-Cancer/2012-04-18T22:02:04-07:00https://dev.oncoprescribe.com/zaltrap%c2%ae-for-second-line-treatment-of-metastatic-crc/2012-04-15T16:24:33-07:00https://dev.oncoprescribe.com/-orafenib-improves-survival-in-advanced-crc/2012-04-15T16:05:23-07:00https://dev.oncoprescribe.com/Intravenous-IV-aflibercept-versus-placebo-in-combination-with-irinotecan/5-FU-FOLFIRI-for-second-line-treatment-of-metastatic-colorectal-cancer-MCRC-Results-of-a-multinational-phase-3-trial-EF/2012-04-14T20:37:24-07:00https://dev.oncoprescribe.com/cleopatra-trial-in-breast-cancer/2012-04-10T06:26:45-07:00https://dev.oncoprescribe.com/oncoprescribe-newsletter/2012-08-21T16:39:45-07:00https://dev.oncoprescribe.com/oncoprescribe-for-all-health-care-professionals/2012-04-15T16:14:16-07:00https://dev.oncoprescribe.com/brentuximab-vedotin-sgn-35-for-hodgkins-lymphoma-and-systemic-anaplastic-large-cell-lymphoma/2020-06-23T17:33:13-07:00https://dev.oncoprescribe.com/brentuximab-vedotin-sgn-35-for-hodgkins-lymphoma-and-anaplastic-large-cell-lymphoma/2020-06-23T17:26:38-07:00https://dev.oncoprescribe.com/Exemestane-for-Breast-Cancer-Prevention-in-Postmenopausal-Women/2011-06-24T16:55:37-07:00https://dev.oncoprescribe.com/breast-cancer-prevention/2011-06-24T15:01:53-07:00https://dev.oncoprescribe.com/BRAF-Mutations-in-Hairy-Cell-Leukemia/2011-06-18T16:15:33-07:00https://dev.oncoprescribe.com/Phase-III-randomized,-open-label,-multicenter-trial-BRIM3-comparing-BRAF-inhibitor-vemurafenib-with-dacarbazine-DTIC-in-patients-with-V600E-BRAF-mutated-melanoma/2011-06-17T11:59:48-07:00https://dev.oncoprescribe.com/improving-survival-in-metastatic-melanoma/2011-06-17T08:02:07-07:00https://dev.oncoprescribe.com/iniparib-plus-chemotherapy-in-metastatic-triple-negative-breast-cancer/2020-05-23T17:50:05-07:00https://dev.oncoprescribe.com/ABIRATERONE-ACETATE-AA-PLUS-LOW-DOSE-PREDNISONE-P-IMPROVES-OVERALL-SURVIVAL-OS-IN-PATIENTS-PTS-WITH-METASTATIC-CASTRATIONRESISTANT-PROSTATE-CANCER-MCRPC-WHO-HAVE-PROGRESSED-AFTER-DOCETAXEL-B/2011-05-06T16:50:06-07:00https://dev.oncoprescribe.com/Dasatinib-versus-Imatinib-in-Newly-Diagnosed-Chronic-Phase-Chronic-Myeloid-Leukemia/2011-05-06T08:10:05-07:00https://dev.oncoprescribe.com/Sunitinib-Malate-for-the-Treatment-of-Pancreatic-Neuroendocrine-Tumors/2011-05-06T08:09:01-07:00https://dev.oncoprescribe.com/Everolimus-for-Advanced-Pancreatic-Neuroendocrine-Tumors/2011-05-06T08:08:25-07:00https://dev.oncoprescribe.com/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/2020-05-23T18:49:38-07:00https://dev.oncoprescribe.com/a-phase-iii-study-embrace-of-eribulin-mesylate-versus-treatment-of-physician-39-s-choice-in-patients-with-locally-recurrent-or-metastatic-breast-cancer-previously-treated-with-an-anthracycline-and/2020-05-23T17:49:52-07:00https://dev.oncoprescribe.com/sipuleucel-t-immunotherapy-for-castration-resistant-prostate-cancer/2020-05-07T08:35:03-07:00https://dev.oncoprescribe.com/Rituximab-maintenance-for-2-years-in-patients-with-untreated-high-tumor-burden-follicular-lymphoma-after-response-to-immunochemotherapy/2011-05-06T08:05:44-07:00https://dev.oncoprescribe.com/Improved-Survival-with-Ipilimumab-in-Patients-with-Metastatic-Melanoma/2011-05-06T08:05:44-07:00https://dev.oncoprescribe.com/Randomized-phase-III-trial-comparing-FOLFIRINOX-F-5FU/leucovorin-%5BLV%5D,-irinotecan-%5BI%5D,-and-oxaliplatin-%5BO%5D-versus-gemcitabine-G-as-first-line-treatment-for-metastatic-pancreatic-adenocarcinoma-M/2011-05-06T08:05:44-07:00https://dev.oncoprescribe.com/Phase-III-trial-of-bevacizumab-BEV-in-the-primary-treatment-of-advanced-epithelial-ovarian-cancer-EOC,-primary-peritoneal-cancer-PPC,-or-fallopian-tube-cancer-FTC-A-Gynecologic-Oncology-Group/2011-05-06T08:05:44-07:00https://dev.oncoprescribe.com/nilotinib-versus-imatinib-for-newly-diagnosed-chronic-myeloid-leukemia/2020-05-23T18:23:31-07:00https://dev.oncoprescribe.com/Prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant-prostate-cancer-progressing-after-docetaxel-treatment-a-randomised-open-label-trial/2011-05-06T08:05:44-07:00https://dev.oncoprescribe.com/results-of-a-randomized-phase-iii-trial-of-nab-paclitaxel-nab-p-and-carboplatin-c-compared-with-cremophor-based-paclitaxel-p-and-carboplatin-as-first-line-therapy-in-advanced-non-small-cell-lun/2020-05-23T18:50:01-07:00https://dev.oncoprescribe.com/new-biomarker-to-predict-cancer-recurrence-or-metastasis/2017-08-01T13:46:12-07:00https://dev.oncoprescribe.com/environment-and-cancer/2017-08-01T13:47:43-07:00https://dev.oncoprescribe.com/breast-cancer-more-is-not-necessarily-better/2011-02-10T18:03:37-07:00https://dev.oncoprescribe.com/maintenance-rituximab/2011-02-02T08:32:02-07:00https://dev.oncoprescribe.com/parp-inhibition-in-triple-negative-breast-cancer/2011-01-28T14:28:40-07:00https://dev.oncoprescribe.com/improving-survival-in-metastatic-pancreatic-cancer/2011-01-20T12:09:27-07:00https://dev.oncoprescribe.com/gvax-vaccine-for-pancreatic-cancer/2011-01-05T15:56:58-07:00https://dev.oncoprescribe.com/everolimus-for-neuroendocrine-tumors/2023-09-15T14:16:47-07:00https://dev.oncoprescribe.com/aggressive-melanoma-in-patients-with-cll/2010-12-27T11:46:13-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-prognosis-in-aml-based-on-gene-signature/2010-12-22T12:32:38-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-identifying-the-origin-of-challenging-tumors/2017-08-01T13:39:27-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-ovarian-cancer-screening/2010-12-13T08:52:49-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-vegf-in-brain-tumors/2010-12-09T17:04:32-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-prostate-cancer-androgen-independent-or-castrate-resistant/2010-12-07T13:37:21-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-pazopanib-in-thyroid-cancer/2010-12-06T07:18:47-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-vandetanib-zactima-in-medullary-thyroid-cancer/2010-12-01T22:13:25-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-improving-progression-free-survival-with-bevacizumab-in-ovarian-cancer-patients/2010-11-30T16:50:12-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-denosumab-approved-for-bone-metastases-in-solid-tumors/2010-11-29T20:10:23-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-eribulin-improves-survival-in-metastatic-breast-cancer/2010-11-25T06:41:11-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-nab-paclitaxel-in-non-small-cell-lung-cancer/2010-11-23T09:27:27-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-anticancer-therapy-with-bisphosphonates/2010-11-22T06:36:13-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-newer-agents-for-hard-to-treat-cancers-sorafenib-to-the-rescue/2010-11-20T08:41:16-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-is-warfarin-making-its-way-out/2010-11-17T20:26:51-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-personalized-therapy-based-on-hpv-status-in-patients-with-head-and-neck-cancer/2010-11-16T15:42:33-07:00https://dev.oncoprescribe.com/oncoprescribe-blog-more-on-romiplostim-for-itp/2010-11-15T16:37:24-07:00https://dev.oncoprescribe.com/personalized-medicine-for-prostate-cancer-patients/2010-11-13T08:45:49-07:00https://dev.oncoprescribe.com/abiraterone-another-promising-agent-in-crpc/2010-11-13T08:47:06-07:00https://dev.oncoprescribe.com/cabazitaxel-another-new-agent-for-crpc/2010-11-13T08:48:44-07:00https://dev.oncoprescribe.com/crpc-a-wave-of-new-agents-but-first-sipuleucel-t/2010-11-13T08:49:19-07:00https://dev.oncoprescribe.com/predicting-chemotherapy-benefit-using-tumor-gene-expression-signature-in-nsclc/2010-11-13T08:51:19-07:00https://dev.oncoprescribe.com/remember-homoharringtonine-it-may-soon-be-in-the-limelight/2010-11-13T08:52:03-07:00https://dev.oncoprescribe.com/mammaprint-multigene-assays-%e2%80%93-on-the-cutting-edge-of-personalized-medicine/2010-11-13T08:52:46-07:00https://dev.oncoprescribe.com/improving-survival-in-advanced-malignant-melanoma/2010-11-13T08:53:26-07:00https://dev.oncoprescribe.com/alk-inhibitors-in-nsclc-%e2%80%93-refining-individualized-therapy/2011-04-08T08:56:36-07:00https://dev.oncoprescribe.com/triple-negative-breast-cancers-%e2%80%93-a-different-breed/2010-11-13T08:55:21-07:00https://dev.oncoprescribe.com/to-treat-or-not-to-treat-stage-ii-colon-cancer-%e2%80%93-molecular-markers-to-the-rescue/2010-11-13T08:56:13-07:00https://dev.oncoprescribe.com/malignant-melanoma-%e2%80%93-an-elusive-disease/2010-11-13T08:57:08-07:00https://dev.oncoprescribe.com/fulvestrant-in-metastatic-breast-cancer-new-dosing-schedule/2010-11-13T08:57:55-07:00https://dev.oncoprescribe.com/more-progress-in-chronic-myeloid-leukemia/2010-11-13T08:58:40-07:00https://dev.oncoprescribe.com/another-shot-at-postmenomausal-hormone-therapy-and-breast-cancer/2010-11-13T09:00:21-07:00https://dev.oncoprescribe.com/bevacizumab-and-cns-metastases/2010-11-13T09:01:23-07:00https://dev.oncoprescribe.com/will-braf-trump-kras-testing-in-metastatic-colon-cancer/2010-11-13T09:01:45-07:00https://dev.oncoprescribe.com/rems-for-romiplostim-nplate%c2%ae-and-eltrombopag-promacta%c2%ae/2010-11-13T09:02:35-07:00https://dev.oncoprescribe.com/53/2010-11-13T09:02:56-07:00https://dev.oncoprescribe.com/eltrombopag-promacta%c2%ae-for-chronic-itp/2010-11-13T09:03:19-07:00https://dev.oncoprescribe.com/just-added-synopsisclinical-relevance-for-arzerra-for-cll/2010-11-13T09:03:46-07:00https://dev.oncoprescribe.com/n9831-trial/2010-11-13T09:04:14-07:00https://dev.oncoprescribe.com/dual-her-2-blockade-in-metastatic-breast-cancer/2010-11-13T09:04:44-07:00https://dev.oncoprescribe.com/anthracyclines-in-breast-cancer/2010-11-13T09:05:27-07:00https://dev.oncoprescribe.com/targeted-agents-in-oncology-and-personalized-medicine/2010-11-13T09:06:09-07:00https://dev.oncoprescribe.com/survival-benefit-with-bevacizumab-plus-interferon/2010-11-13T09:06:59-07:00https://dev.oncoprescribe.com/avoren-study-avastinbevacizumab-plus-interferon-alfa/2010-11-13T09:07:27-07:00https://dev.oncoprescribe.com/survival-benefit-with-sunitinib/2010-11-13T09:07:53-07:00https://dev.oncoprescribe.com/pemetrexed-alimta-maintenance/2010-11-13T09:08:33-07:00https://dev.oncoprescribe.com/avastin-for-kidney-cancer/2010-11-13T09:08:58-07:00